Statera BioPharma Inc (STAB)
0.0007
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Statera BioPharma SG&A Expense (Quarterly): 1.738M for Sept. 30, 2022
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2022 | 1.738M |
| June 30, 2022 | 2.335M |
| March 31, 2022 | 3.797M |
| December 31, 2021 | 4.699M |
| September 30, 2021 | 5.494M |
| Date | Value |
|---|---|
| June 30, 2021 | 4.214M |
| March 31, 2021 | 4.078M |
| December 31, 2020 | 3.600M |
| September 30, 2020 | 1.564M |
| March 31, 2020 | 0.0839M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.0839M
Minimum
Mar 2020
5.494M
Maximum
Sep 2021
3.160M
Average
3.698M
Median
SG&A Expense (Quarterly) Benchmarks
| Humanigen Inc | 3.719M |
| Cantabio Pharmaceuticals Inc | 0.16M |
| Affymax Inc | -- |
| RVL Pharmaceuticals PLC | 13.89M |
| Scopus BioPharma Inc | 0.9359M |